Evidence map›Paper›PMID 34454432›Full record

Observational studyBMC infectious diseases2021

Different epidemiological profiles in patients with Zika and dengue infection in Tapachula, Chiapas in Mexico (2016-2018): an observational, prospective cohort study.

Pablo F Belaunzarán-Zamudio, Héctor Armando Rincón León, Sandra Caballero Sosa, Emilia Ruiz, José Gabriel Nájera Cancino, Paul Rodriguez de La Rosa, María de Lourdes Guerrero Almeida, John H Powers, John H Beigel, Sally Hunsberger and 9 more

Registry-linked trialAbstract readObservational Study
In one paragraph

Observational study in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02831699 (The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02831699 completednot on this map

The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico (Zik01)

TypeobservationalSponsorMexican Emerging Infectious Diseases Clinical Research NetworkRan2016 to 2019Enrolled600ConditionsZika Virus Disease (Disorder), Dengue, Chikungunya
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Pablo F Belaunzarán-ZamudioDepartamento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. p.belaunz@infecto.mx.ORCID http://orcid.org/0000-0003-4775-4734
Héctor Armando Rincón LeónUnidad de Medicina Familiar No.11, Instituto Mexicano del Seguro Social, Tapachula, Chiapas, Mexico.
Sandra Caballero SosaClínica Hospital Dr. Roberto Nettel Flores, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Tapachula, Chiapas, Mexico.
Emilia RuizHospital General de Tapachula, Tapachula, Chiapas, Mexico.
José Gabriel Nájera CancinoHospital Regional de Alta Especialidad Ciudad Salud, Tapachula, Chiapas, Mexico.
Paul Rodriguez de La RosaHospital Regional de Alta Especialidad Ciudad Salud, Tapachula, Chiapas, Mexico.
María de Lourdes Guerrero AlmeidaDepartamento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
John H PowersLeidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
John H BeigelNational Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
Sally HunsbergerNational Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
Karina TrujilloHospital Regional de Alta Especialidad Ciudad Salud, Tapachula, Chiapas, Mexico.
Pilar RamosDepartamento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Fernando J Arteaga-CabelloDepartamento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Alexander López-RobleroHospital Regional de Alta Especialidad Ciudad Salud, Tapachula, Chiapas, Mexico.
Raydel Valdés-SalgadoWestat, Rockville, MD, USA.
Hugo Arroyo-FigueroaMexican Emerging Infectious Diseases Clinical Research Network (La Red), Mexico City, Mexico.
Eli BecerrilMexican Emerging Infectious Diseases Clinical Research Network (La Red), Mexico City, Mexico.
Guillermo Ruiz-PalaciosDepartamento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Mexican Emerging Infectious Diseases Clinical Research Network (La Red)

Funding

NCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003INIH HHS HHSN261200800001ENIH HHS HHSN261201500003I
6 · The paper itself

Abstract

backgroundThe introduction of Zika and chikungunya to dengue hyperendemic regions increased interest in better understanding characteristics of these infections. We conducted a cohort study in Mexico to evaluate the natural history of Zika infection. We describe here the frequency of Zika, chikungunya and dengue virus infections immediately after Zika introduction in Mexico, and baseline characteristics of participants for each type of infection.

methodsProspective, observational cohort evaluating the natural history of Zika virus infection in the Mexico-Guatemala border area. Patients with fever, rash or both, meeting the modified criteria of PAHO for probable Zika cases were enrolled (June 2016-July 2018) and followed-up for 6 months. We collected data on sociodemographic, environmental exposure, clinical and laboratory characteristics. Diagnosis was established based on viral RNA identification in serum and urine samples using RT-PCR for Zika, chikungunya, and dengue. We describe the baseline sociodemographic and environmental exposure characteristics of participants according to diagnosis, and the frequency of these infections over a two-year period immediately after Zika introduction in Mexico.

resultsWe enrolled 427 participants. Most patients (n = 307, 65.7%) had an acute illness episode with no identified pathogen (UIE), 37 (8%) Zika, 82 (17.6%) dengue, and 1 (0.2%) chikungunya. In 2016 Zika predominated, declined in 2017 and disappeared in 2018; while dengue increased after 2017. Patients with dengue were more likely to be men, younger, and with lower education than those with Zika and UIE. They also reported closer contact with water sources, and with other people diagnosed with dengue. Participants with Zika reported sexual exposure more frequently than people with dengue and UIE. Zika was more likely to be identified in urine while dengue was more likely found in blood in the first seven days of symptoms; but PCR results for both were similar at day 7-14 after symptom onset.

conclusionsDuring the first 2 years of Zika introduction to this dengue hyper-endemic region, frequency of Zika peaked and fell over a two-year period; while dengue progressively increased with a predominance in 2018. Different epidemiologic patterns between Zika, dengue and UIE were observed. Trial registration Clinical.Trials.gov (NCT02831699).

Indexed as

Chikungunya FeverDengueDengue VirusZika VirusZika Virus InfectionCohort StudiesFemaleHumansMaleMexicoProspective StudiesChikungunyaDengueEmerging diseasesMexicoOutbreakZika

Identifiers

PMID34454432
PMCPMC8397877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.